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Introduction
The most widely studied biomarker among various 
types of breast cancer prognostic biomarkers is the human 
epidermal growth factor receptor 2 HER2 gene (Wolff et 
al., 2013). Approximately, 15-30% of breast cancers show 
amplification in HER2 gene, leading to poor prognosis in 
patients with breast cancers (Piccart et al., 2002; Chang 
et al., 2004; Yarden et al., 2004). Amplification of this 
gene is associated with various clinical effects including 
disease progression, increased metastatic potential, shorter 
survival, higher rates of relapse, high-grade tumors, 
resistance to Tamoxifen therapy, and surprisingly good 
response to trastuzumab targeted therapy (Ferrero-Pous et 
al., 2000; Ariga et al., 2005; Huang et al., 2005). Targeted- 
therapy using monoclonal antibody against HER2, 
trastuzumab (Herceptin) and the dual tyrosine kinase 
inhibitor (HER1 and HER2)-Lapatinib is an effective 
treatment for patients with HER2 gene amplification 
(Slamon et al., 2001; Yarden et al., 2004; Bilancia et al., 
2007). But, both drugs have been found to be effective 
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Abstract
 Background: HER2/neu overexpression on cell membranes of breast cancer cells is due to HER2/neu gene 
amplification and it is important to identify potential candidates for anti HER2 therapy with trastuzumab. 
IHC, FISH and CISH are standard FDA approved assays currently used to determine HER2 status in routine 
practice. The aim of this study was to determine HER2 gene amplification, using the CISH method in breast 
carcinoma samples which had IHC +2 reactions. Materials and Methods: This study was conducted from 2008-
2010 using 334 consecutive breast carcinoma samples referred from local laboratories to Mehr Hospital. CISH 
assays were performed for all cases, and IHC tests were also done for determining efficacy and accuracy of 
local labs. HER2 status in local IHC tests was compared with central IHC and CISH results. Results: Of 334 
breast cancer patients, 16 were negative for HER2 IHC (0, +1), 201 cases were equivocal (+2), and 31 positive 
(+3). Of 334 referral cases, 88 were CISH positive (26.3%) and 246 were CISH negative (73.7%). Of 201 IHC 
+2 cases, HER2 gene amplification was observed in 42 cases (kappa: 0.42). A 29.9% concordance was found 
between local IHC and central IHC. Sensitivity and specificity of local IHC were 90% and 53.8%, respectively. 
Conclusions: Low accuracy of IHC results in local labs was associated with the following factors: using former 
FDA-approved criteria for HER2 interpretation, utilizing non-validated kits, and lack of any quality assurance 
program. Therefore, following the new 2014 ASCO/CAP guideline and comprehensive quality assurance should 
be implemented to ensure accuracy of HER2 testing. 
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only in tumors showing true gene amplification. So, 
it is important to find patients who may respond well 
to targeted therapy. To detect HER2 status, following 
methods are used: a) gene analysis (Chromogenic in situ 
hybridization (CISH), Fluorescent in situ hybridization 
(FISH), Polymerase chain reaction (PCR), Southern blot, 
and detection of messenger RNA by RT-PCR or Northern 
blot), b) direct detection of HER2 protein on the cell 
membrane by western blot and immunohistochemistry 
(IHC). IHC, FISH and CISH are the most common 
methods to determine HER2 status (Ivkovic-Kapicl 
et al., 2007). HER2 protein can be stained by various 
immunohistochemical methods; Ventana pathway and 
Hercep Test are FDA-approved kits for the assessment of 
HER2 gene by IHC (O’Malley et al., 2008). PathVysion 
and Invitrogen are FDA-approved kits for HER2 gene 
detection by FISH and CISH, respectively. IHC is less 
expensive and more widely available but has poorer 
reliability (Lan et al., 2005). This has led to debate about 
the best testing strategy, fueled by the high cost of the 
drug. The ASCO/CAP study data from 2000 to 2005 
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jointly with adjuvant randomized trials, demonstrated that 
as many as 15% to 20% of the HER2 assays performed in 
the field may be incorrect when the same specimens were 
re-evaluated in a high-value central laboratory (Wolff et 
al., 2006). Regarding the high-rate of false-positive IHC 
results based on original FDA-approved criteria, breast 
cancer’s high cost of treatment, and Trastuzumab-related 
cardiotoxicity, the College of American Pathologists 
(CAP) and the American Society of Clinical Oncology 
(ASCO) provided guidelines for HER2 testing (Wolff 
et al., 2006). These updated guideline recommendations 
were published in 2007 to avoid number of false positive 
IHC cases (Vogel, 2010). Equivocal IHC results (+2) can 
be seen in 15% of total breast cancers, of whom 24%-
44% show amplification (Lan et al., 2005; Wolff et al., 
2006). Although the results obtained using IHC, FISH and 
CISH methods show 90-95% concordance, the primary 
differences are appeared to be due to (+2) IHC results. So, 
most guidelines recommend testing all IHC+2 samples 
with FISH or CISH (Wolff et al., 2006). The aims of this 
paper are to determine the frequency of amplifications in 
the study group and to examine the differences between 
the results of this study and findings obtained in other 
studies. Finally we explain how far we are from ASCO/
CAP new guideline. 
Materials and Methods
The purpose of this experimental trial is to detect 
HER2 biomarker in tissue samples of 334 patients with 
breast cancer who were referred to Pathology department 
of Mehr hospital, since the implementation of CISH 
technique, between March 2009 and Feb 2011. This study 
used dual CISH as the gold standard method to determine 
the accuracy of the IHC test results. In brief, IHC and 
CISH tests performed in Mehr laboratory are called central 
tests while IHC tests performed in other laboratories are 
called local IHC tests. Central laboratory IHC staining 
test has been validated by FISH test and the quality of 
CISH technique has been comprehensively controlled 
by NEQAS. The study is looking at tissue samples that 
were collected from women referred to this center with a 
primary diagnosis of breast cancer. Tissue samples were 
divided into two groups: a) First group included IHC+2 
cases referred to CISH. Actually, local IHC results were 
available in this group of samples. b) Second group 
consisted of samples in which local IHC results were not 
available and just referred for CISH test. CISH test along 
with IHC staining were carried out in both group of tissue 
samples to evaluate the status of target population (IHC+2) 
and assess performance of laboratories for accuracy and 
precision.
Test methods
Paraffin blocks were cut into 5-6 micron sections (at 
least 2 sections) in order to evaluate the HER2 marker. All 
original breast tumor tissues with either modified radical 
mastectomy or breast conserving surgery were sectioned 
to confirm the diagnosis of invasive carcinomas
Chromogenic in situ hybridization
The test has been performed by the use of 
chromogenic in-situ hybridization, according to Zyto 
Dot® 2C SPEC HER2/CEN 17 dual Probes Kit protocol. 
(Zytovision company-Germany) The PD-12 probe 
contains digoxigenin-labled polynucleotides, which 
target sequences of the HER2 gene and DNA-labeled 
polynucleiotides, which target alpha-satellites of the 
centromere of chromosome 17 led to the formation of 
green and red signals that can be visualized by light 
microscopy using a 40x objective. All of these reactions 
were carried out within 2 days and following 4 steps 
according to kit protocol (www.zytovision.com).
The CISH hybridization signal of one single copy of 
a HER2 gene appears as a dark green-colored distinct 
dot- shaped signal, while the signal of one single copy of a 
chromosome 17 centromeric region appears as bright red- 
colored distinct dot-shaped signal which can be clearly 
distinguished from the background counterstained with 
hematoxylin. All slides were reviewed by two experienced 
pathologists and results were recorded and scored 
according to the new 2014 ASCO/CAP guidelines. In brief 
, the number of CEP17 and HER2 signals counted in 20 
non -overlapping invasive cancer cell nuclei, using at least 
three distinct tumor fields (when possible). HER2 signal 
heterogeneity was disregarded from this study. Where the 
mean HER2/CEP17 ratio in any field is 2 or greater, the 
tumor regarded as amplified and ratio less than 2 regarded 
as not amplified when her2 copy number is equal or less 
than 4. Cases with ratio less than 2 and her2 copy number 
between 4-6 regarded as equivocal borderline results and 
final decision on the degree of amplification was made 
after counting an additional 20 nuclei according to new 
2014 ASCO/CAP guideline(Wolff et al., 2013).
Immunohistochemistry 
IHC staining was performed on paraffin-embedded 
breast cancer tissue specimens using polyclonal rabbit 
antihuman c-erbB-2 oncoprotein (Dako A0485 clone). 
IHC staining procedure was conducted according to Dako 
Envision kit protocol in the following steps. Finally, the 
slide was counterstained with hematoxylin and reviewed 
by two pathologists under light microscope at 40x 
magnification. IHC results were recorded and scored 
according to the new 2014 ASCO/CAP guidelines (Wolff 
et al., 2013). In brief Positive staining, i.e. “3+”, was 
defined as strong, complete, homogeneous membrane 
staining (“chicken-wire” pattern) in >10% of cells. 
Equivocal staining, i.e. “2+”, was assessed as moderate/
strong, incomplete membrane staining in less than 10% 
of cells. No staining, i.e. “0”, or weak, incomplete 
membrane staining, i.e. “1+”, in any percentage of cells 
were categorized as negative.
Statistical analysis
After data collection, frequency tables, graphs and 
statistics were used to summarize and organize data. 
Chi-square and McNemar’s tests were used for statistical 
analysis. Sensitivity and specificity of local and central 
IHC tests, and finally the concordance rate between local 
and central IHC tests were determined. Concordance 
calculation performed based on compatibility rate 
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between IHC and CISH on all positive and negative cases, 
and finally between local and central laboratory IHC 
results, when the overall percent agreement is similar. 
Kappa values are interpreted as follows: 0-0.20, poor 
agreement, 0.21- 0.45, moderate agreement, 0.46-0.75, 
high agreement and 0.76-0.99, almost perfect agreement. 
The identity of patients is not revealed in this study.
Results 
Of 337 cases, 1 case identified to have chromosome 
17 polysomy and 2 cases with equivocal CISH results 
were discontinued from the study, so data analysis was 
only performed on the remaining 334 breast cancer 
specimens. Based on local and central IHC method and 
scoring system, the frequency distribution of HER2 
protein among cases referred to Mehr laboratory has been 
shown in Table1. Among of 334 cases, 88 (26.3%) showed 
HER2 gene amplification by CISH and 246 (73.7%) 
showed no amplification. The frequency of HER2 gene 
amplification by CISH method between local IHC2+ 
and central IHC2+ are 20.9% and 26.3%, respectively 
(figure1). The following figure shows frequency of HER2 
gene amplification.
Comparison between local IHC and CISH
14 out of 16 (87.5%) samples that were reported 
negative by local IHC (0 or +1), were also CISH negative 
and among 30 cases scored as IHC positive (+3), only 
18 cases (60%) exhibited HER2 gene amplification. The 
results using local IHC and CISH for IHC (0, +1, and +3) 
samples showed a concordance of 69.6%. The comparison 
between results reported by local HER2 IHC test ( without 
considering IHC+2) and CISH revealed that there was 
a significant correlation between HER2 score in breast 
cancer specimens by local IHC and CISH (P=0.002). 
IHC sensitivity and specificity were determined 90% 
and 53.8%, respectively and statistical analysis showed 
moderate concordance between local testing with IHC 
and CISH results (Kappa= 0.42).
Comparison between central IHC and CISH
These analyses were also performed for central 
laboratory HER2 IHC testing results. According to 
findings, among 177 cases that were reported negative 
(IHC+1, 0) by central IHC, 169 cases (95.5%) remained 
negative on the CISH test (without amplification) and 
among of 62 central IHC-positive cases, 55 (87.7%) 
remained positive on the CISH test. The concordance 
between central IHC and CISH for all positive and 
negative cases (IHC+3, +1 and 0) were reported 93.7%. 
Figure 1. The Frequency of HER2 Status by IHC 
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Table 1. The Frequency of HER2 Status by IHC 
Method
Grade IHC local IHC central
 Number Percent Number Percent
0, +1 16 4.8 177 53
2 201 60.1 95 28.4
3 30 8.9 62 18.6
Not graded 88 26.2 0 0
Total 334 100 334 100
*IHC: Immuno-Histo-Chemistry
Table 2. Local and Central IHC Characteristics in Comparison with CISH as a Gold Standard Method
 Sensitivity Specificity IHC+3 IHC 0, +1,  IHC 0, +1, +3 Discordant  Concordance Kappa
  Concordance  Concordance Concordance results* rate with CISH** value
Local IHC 90% 53.80% 60% 87.50% 69.60% 30% Moderate 0.42
Central IHC 87.30% 96% 88.70% 95.50% 93.70% 6.30% Almost perfect 0.84
*Discordant Results are related to IHC +3 cases not showing amplification by CISH and vice versa, ** Chromogenic in-situ hybridization
Table 3. Retested Central IHC Results for Referral HER2 
Local IHC 0 and +1 +2 +3 Totally
Central IHC Number Percent Number Percent Number Percent Number Percent
+1and 0 10 62.5 5 31.25 1 6.25 16 100
+2 121 60.19 51 25.37 29 14.42 201 100
+3 4 13.33 13 43.33 13 43.33 30 100
Totally 135 54.65 69 27.93 43 17.4 247 100
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Another analysis showed that there was almost perfect 
concordance between central IHC and CISH results 
(Kappa=0.84). Sensitivity and specificity of central IHC 
were 87.3% and 96%, respectively (Table2).
Comparison of local IHC result with central IHC result
The comparison between the results of IHC cases 
retested centrally to determine HER2 status and local 
IHC (+3, +2, and 0) showed that there was statistically 
significant difference between two groups(P<0.0001). But, 
there was actually no significant difference when IHC+2 
cases were excluded from the study (P=0.37). The findings 
show that large differences between local and central 
IHC assays are due to IHC+2 cases, and all cases scored 
as IHC positive (+3) and negative (+1, 0) have relatively 
similar results (Table3). The total concordance between 
local and central IHC was 29.9% and the highest rate of 
discordance was between the results of local IHC +2 and 
central IHC+2 (74.6%).
Discussion
The advances in prognostic factors and therapeutic 
options for human breast cancer have resulted in finding 
more accurate methods to assess the HER2 status. In many 
studies, IHC has been established as first test to detect 
HER2 over expression on the surface of tumor cells. 
IHC method with all the advantages of wide availability 
and low cost that make it preferred first test, owing to 
technical difficulties and interobservation variation among 
pathologists in interpretation may provide misleading 
results. Thomson et al wrote that IHC staining cannot be 
adopted for cases scored as 2 in routine clinical practice 
and supplementary methods like FISH should be used 
as well (Thomson et al., 2001). Kakar et al. (2000) 
concluded that IHC staining is an appropriate method for 
the assessment of HER2 status but FISH method should 
be performed for cases scored less than +3 (especially 
+2 by IHC) to achieve better results (Kakar et al., 2000). 
CISH, which is a new development in the detection of 
HER2, is well-suited for use as an alternative to FISH 
(Tanner et al., 2000; Kumamoto et al., 2001; Dandachi et 
al., 2002; Zhao et al., 2002; Arnould et al., 2003; Gupta 
et al., 2003; Park et al., 2003; Madrid and Lo, 2004; 
Vera-Roman and Rubio-Martinez, 2004). CISH method 
has several advantages over FISH, including the use of 
ordinary microscope; the method is less cumbersome and 
cost effective, as well as the signal intensity is permanent. 
The concordance between CISH and FISH ranged from 
85% to as high as 100%. The first study on CISH method 
was conducted by Taner et al. in 2000 followed by several 
researches on the priority of CISH over previous methods 
including FISH (Tanner et al., 2000).
The results of the study conducted by Madrid et al. 
on 160 cases using CISH and its comparison with IHC 
staining showed that CISH due to high accuracy and 
diagnostic yields in can play a complementary test in 
cases with equivocal IHC status (Madrid and Lo, 2004). 
By 2005, “Bargava” et al. (2005) reported that both 
CISH and FISH have the same result of HER2 gene 
amplification in human breast cancer (Bhargava et al., 
2005). The results of the study conducted by Lakso et al 
using CISH and FISH along with Dandachi et al study on 
173 breast cancer specimens using IHC and CISH showed 
the perfect concordance (k=0.82 and 0.88, respectively) 
(Dandachi et al., 2002; Laakso et al., 2006). Concordance 
between IHC and ISH has been reviewed in several studies 
and the results are compared with the present study and 
summarized in Table4.
Our analysis showed that 26.3% of all specimens 
irrespective of central or local IHC result had HER2 
gene amplification by CISH which is in expected range 
of 15% to 30% mentioned in most studies (Piccart et al., 
2002; Chang et al., 2004; Yarden et al., 2004). From 201 
IHC 2+ cases referred to our center revealed that 20.9% 
of them had amplification by CISH, which is lower than 
expected range of 24% to 44% seen in most studies (Lan 
et al., 2005; Wolff et al., 2006). Amplification rate seen 
in central IHC+2 cases was found to be 26.3% which was 
within the expected range
Discordant Results: 3+IHC cases that are FISH non-
amplified and IHC-negative cases that are FISH-amplified 
contain 1.5%-19.2% of all cases in the studies (Reddy 
et al., 2006; Mayr et al., 2009). In the current study, 
discordant results between CISH and local IHC testing 
as well as between CISH and central IHC testing were 
30% and 6.3%, respectively. The comparison between 
the results of this study and the results from other studies 
show that the accuracy of IHC tests performed in the local 
laboratories due to following factors is not met criteria of 
ASCO/CAP guidelines for HER2 assessment:
1. As the majority of local laboratories used different 
ASCO/CAP guidelines (cut off point 10% or 30% for 
HER2 positivity) to interpret HER2 IHC tests, there 
was high rate of false- positive cases (discordance result 
among 3+IHC was 40%). This can explain the significant 
difference between local and central IHC results. The 
removal of cases scored as 2+ in IHC showed no significant 
differences between local and central IHC (ASCO/CAP 
new guidelines were used in central laboratory).
2. ASCO/CAP guidelines have been developed based 
on the comparison between IHC and FISH. Although there 
is high concordance between CISH and FISH and CISH 
Table 4. The comparison between IHC and in situ 
hybridization tests(FISH or CISH) in various studies
Study Positive Concordance 
Negative 
Concordance
Overall 
Concordance
O'Malley 0.861 0.985 -
Roche - - 0.66
Madrid 0.725 1 0.862
Laakso - - 0.91
Panjwani 0.939 0.859 -
Ridolfi 1 0.982 0.89
Dandachi 0.917 1 0.955
ASCO/CAP 
guidline 0.9 0.95 0.95
Local Our 
Study
0.6 0.875 0.696
Central 0.887 0.955 0.937
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is an alternative to FISH, the differences in the results can 
be attributed to whatever mentioned above.
3. Using non-validated HER2 kits or antibodies. 
Although insufficient data is available, it seems that the 
type of antibody used in various laboratories to perform 
IHC staining can affect the accuracy of the test. Using 
FDA-approved kits such as Dako Hercept test can 
overcome this problem.
4. Preanalytical factors especially duration and type 
of tissue fixation influence HER2 receptor status by IHC/
CISH tests. These preanalytical variables which were 
uncontrollable in this study were regarded as major factors 
influenced the IHC accuracy.
5. The last but not the least factor is absence of 
comprehensive external and internal quality control 
programs in local laboratories. This can directly affect 
Her2 results.
The comparison between sensitivity (90%) and 
specificity (57.7%) of local IHC with central IHC show 
that there is a high rate of false-positive HER2 in the 
local laboratories which not only causes unnecessary 
catastrophic overtreatment but also waste a lot of money. 
Such problems may lead to CISH or FISH test as the 
first step in HER2 assessment. Farshid et al in the article 
published in 2010 in Australia suggested one of the ISH 
methods (CISH or FISH) as the first step for HER2 
assessment (Farshid et al., 2010).
Our results revealed that false positive HER2 test in 
our country is increased; however ministry of health is 
now trying to urge laboratories to follow ASCO/CAP 
guidelines. Regarding to importance of inaccurate HER2 
testing led to inappropriate costly treatment and adverse 
unwanted drug toxicity, new guidelines of 2014 ASCO/
CAP have to be strictly taken into account for every 
laboratories are intended to do IHC test for HER2. The 
concordance between IHC tests performed at various 
centers and gold standard CISH/FISH tests should be 
taken into consideration as well.
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